Take Homes in Infection

Take Homes in Infection

Source:

Chey WD, et al. Vonoprazan dual and triple therapy for Helicobacter pylori Eradication. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021; Las Vegas (hybrid meeting).

Disclosures: Foster reports no relevant financial disclosures.
November 24, 2021
1 min watch
Save

VIDEO: Vonoprazan-based therapy promising for H. pylori eradication

Source:

Chey WD, et al. Vonoprazan dual and triple therapy for Helicobacter pylori Eradication. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021; Las Vegas (hybrid meeting).

Disclosures: Foster reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, C. Jonathan D. Foster, DO, FACOI, discussed a study on the use of vonoprazan-based regimens for the treatment of Helicobacter pylori infection presented at the ACG Annual Scientific Meeting.

“This study was very interesting and is going to bring a new perspective to the market in the treatment of H. pylori,” Foster, medical director of gastroenterology and advanced endoscopy at Jefferson Health New Jersey, told Healio.

In the study, the researchers evaluated the efficacy and safety of vonoprazan (Takeda) dual and triple therapy, as compared with lansoprazole triple therapy, in patients with treatment-naïve H. pylori infection. The study met its primary endpoint, with results demonstrating the noninferiority of both vonoprazan dual and triple therapy to lansoprazole triple therapy in patients with H. pylori that was not resistant to clarithromycin or amoxicillin.

Additionally, the researchers found that both vonoprazan regimens were superior to lansoprazole triple therapy in patients with clarithromycin-resistant strains as well as in the overall patient population. The treatment also appeared to be safe when compared with lansoprazole triple therapy.

“This medication in the future is going to really give us a leg up on the treatment of H. pylori,” Foster said. “This medication will benefit this patient population, especially those with clarithromycin-resistant strains and really set a precedent in helping treat patients with H. pylori, thereby preventing peptic ulcer disease and malignancy.”